Posted by AGORACOM-JC
at 7:21 AM on Wednesday, October 14th, 2020
Announced the signing of a reseller agreement with Sticky Media, a digital and physical sign manufacturer based in Montreal, Canada with over 1500 clients in the last 15 years including Psycho Bunny, Vans , Dominos, and Pajar
“With over 1500 clients, Sticky Media is one of the leading signage companies in Canada and well positioned to market AR to their new and existing clientele” stated ImagineAR CEO and Founder Alen Paul Silverrstieen.
VANCOUVER, BC and ERIE, Pa., Oct. 14, 2020 –ImagineAR(CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables businesses to instantly create their own mobile phone AR campaigns, is pleased to announce the signing of a reseller agreement with Sticky Media, a digital and physical sign manufacturer based in Montreal, Canada with over 1500 clients in the last 15 years including Psycho Bunny, Vans , Dominos, and Pajar.
“We consider the offer of this AR technology to be extremely timely and valuable. The current pandemic is forcing marketing teams to be even more creative in the way they engage consumers. ImagineAR reality tools will provide new and creative ways to engage with customers during this difficult time of Social Distancing”, said Vincent Bonanno, Sales Director of Sticky Media. “We believe that our partnership will address an exciting and new model to help maximize the consumer experience in the retail, food service and media industries.”
“With over 1500 clients, Sticky Media is one of the leading signage companies in Canada and well positioned to market AR to their new and existing clientele” stated ImagineAR CEO and Founder Alen Paul Silverrstieen.
This press release is available on the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About Sticky Media
Sticky Media is a leader for all visual media needs. The company’s priority is to offer the highest quality products and services at competitive prices to ensure our customer’s full satisfaction. Services include vehicle wraps, printing, lettering, fixtures, retail, window, pop, signage and more.
Believing that diversity as well as close collaboration with our clients is the key to success; we not only integrate our clients’ marketing strategies using the latest in print and digital technologies but strive to always exceed expectation with high impact “outside of the box” solutions, creative concept development, combined with top quality print technology and services. As ecological moralists, we take a lot of pride in that all mass production is done with strategy and a minimal carbon footprint approach.
Always taking into account the fast paced environments of our clients, we pride ourselves on helping our customers make the impossible, possible by delivering on tight deadlines and helping to find creative solutions to fulfill requests, no matter how intricate.
Our bottom line is respect for our art form and the planet as well as a professional and customized approach to any mandate handed to us. This is what has earned us a reputation as trend setting visual communication providers in North America over the past 15 years, largely with the help of our loyal clients.
Innovative ideas, technology and street credibility identify our signature approach. Our portfolio is the reference. To learn more, visit stickymedia.ca
About ImagineAR
ImagineAR Inc. (IP:CSE) (IPNFF: OTCQB) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies. ImagineAR is available as an SDK to be integrated into existing mobile apps.
All trademarks of the property of respective owners.
We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by Imagine AR management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 9:11 AM on Tuesday, October 13th, 2020
Peekaboo Beans’ Chief Executive Officer and President, Traci Costa, is scheduled to present on Thursday, October 15th at 2:30 PM EST. Ms. Costa will also be fielding investor questions during the one-day virtual conference hosted by Gravitas Securities Inc.
Vancouver, British Columbia–(October 13, 2020) – Peekaboo Beans Inc. (CSE: BEAN) (“PK Beans” or the “Company”) a responsible and innovative children’s apparel brand, is pleased to announce it will be participating in the Gravitas Technology and Diversified Investor Day taking place Thursday, October 15th, 2020 virtually.
Peekaboo Beans’ Chief Executive Officer and President, Traci Costa, is scheduled to present on Thursday, October 15th at 2:30 PM EST. Ms. Costa will also be fielding investor questions during the one-day virtual conference hosted by Gravitas Securities Inc. “I am looking forward to sharing our growth strategy with investors at the Gravitas Technology and Diversified Investor Day,” said Ms. Costa. “With the success of our recently launched rebranded fall collection, the Gravitas Technology and Diversified Investor Day is an ideal venue to communicate our progress to investors.”
This year’s Gravitas Technology and Diversified Investor Day will feature several leaders in Technology and Diversified industries and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com
Conference Details:
Event: Gravitas Technology and Diversified Investor Day (virtual)
PK Beans is an innovative children’s apparel brand with a focus on environmentally responsible clothes that are intentionally designed to inspire play. Through an omni-channel approach, Peekaboo Beans engages sellers through social platforms, including Instagram and Facebook, as well as online retailers, to maximize revenue and build brand loyalty. The Company works to promote a playful lifestyle for children by designing comfortable clothes that are built to last.
On behalf of the Board of Directors, Peekaboo Beans Inc. Ms. Traci Costa, President and CEO (604) 279-2326
For more information, please contact the Company at:[email protected] 1-604-279-2326
Reader Advisory
This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:24 AM on Tuesday, October 13th, 2020
Announced the signing of a referral agreement with leading UK-based SG-retail to expand Loop’s services and products into the UK and Europe
SG-retail will assist Loop with its efforts to establish a strong presence in Europe and take advantage of recent momentum in the US and Canada
SG-retail has worked with many of the world’s leading retailers and consumer brands to grow “customer engagement” by providing digital marketing, go-to-market strategy and consulting support, “big data” insight and analytics, mobile marketing, content, loyalty & CRM advisory services
Retailers include: Virgin Megastores, Tesco, Kroger, Sephora, Sainsbury, Asda, Morrisons, John Lewis, Waitrose, Boots, Woolworths, Coles, Petrovich, Esprit, and Net-a-Porter
VANCOUVER, British Columbia, Oct. 13, 2020 — Loop Insights Inc. (MTRX:TSXV) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive automated marketing, contact tracing, and contactless solutions to the brick and mortar space, announces the signing of a referral agreement with leading UK-based SG-retail to expand Loop’s services and products into the UK and Europe. SG-retail, led by retail industry veteran Steve Gray, will assist Loop with its efforts to establish a strong presence in Europe and take advantage of recent momentum in the US and Canada.
LOOP POISED TO TAKE ADVANTAGE OF SG-retail ESTABLISHED NETWORK OF RETAIL ADVISORY AND MARKETING CLIENTS INCLUDING SUPERMARKETS, FASHION BRANDS, AND SPECIALTY RETAILERS
SG-retail is led by Steve Gray, a CPG (Consumer Packaged Goods) expert and globally recognized leading innovator in customer loyalty, CRM data analytics, and personalization in the retail sector.
SG-retail has worked with many of the world’s leading retailers and consumer brands to grow “customer engagement” by providing digital marketing, go-to-market strategy and consulting support, “big data” insight and analytics, mobile marketing, content, loyalty & CRM advisory services.
SG-retail supports clients with solution partners like Loop Insights that have a unique capability, data, or IP that can help create value for customers and shareholders. Loop will become part of SG-retail’s leading-edge technology partner list that helps its clients engage more effectively with their customers. SG-retail will introduce and resell Loop’s services to clients that include many of the world’s leading brands as follows:
Retailers – Virgin Megastores, Tesco, Kroger, Sephora, Sainsbury, Asda, Morrisons, John Lewis, Waitrose, Boots, Woolworths, Coles, Petrovich, Esprit, and Net-a-Porter
Consumer Brands – P&G, PepsiCo, Barilla, HBOS, British Gas, Rank, Paddy Power Betfair, The AA, and Sky
Loyalty & Rewards Programs – British Airways/Avios, Tesco Clubcard, Nectar, Club Carrefour, Esprit Friends, Boots Advantage Card & Quidco.
Steve Gray, Managing Director of SG-retail, states, “The timing for this could not be any better as our retail and brand clients across Europe are desperately searching for just the type of innovative retail solutions that Rob and his team at Loop have built. From AI-based retail insights and analytics to consumer engagement and safety-focused reopening technologies such as Loop’s contactless solutions with venue tracing. I believe that Loop is well-positioned to turn a lot of heads and gain a substantial market share in Europe, and I am thrilled to assist these efforts, as our clients will no doubt quickly see the power of Loop just as I have, and I expect we will make great traction here in Europe.”
SG-retail MANAGING DIRECTOR STEVE GRAY ALSO JOINS LOOP INSIGHTS ADVISORY BOARD TO HELP STEER MARKET STRATEGIES FOR LOOP RETAIL ANALYTICS & ENGAGEMENT
In addition to engaging SG-retail to create brand, product, and company awareness of Loop and its market-leading products and services, company Managing Director Steve Gray will join Loop’s Advisory Board to help steer overall market strategies for Loop’s retail analytics and engagement technologies, which have been gaining momentum in North America as evidenced by recent announcements. Steve is widely regarded as a Retail & Fast-Moving Consumer Goods (fmcg) industry expert, having worked for and with such retail and fmcg brands as Carrefour, Metro, Morrisons, Waitrose, Woolworths Australia, Boots, DSG, BP, British Gas, and British Airways/Avios. His Advisory role with Loop will provide another proven retail veteran to an already impressive list of experts leading Loop’s overall market strategies.
Rob Anson, CEO of Loop Insights, stated, “Having Steve Gray and his team at SG-retail join Loop at this pivotal time in our growth is nothing short of monumental. Loop’s recent explosive growth across the spectrum is a testament that our business fundamentals and strategies are taking hold. We expect Steve and SG-retail to be a strong contributor to implementing and guiding those same strategies abroad as we explore the UK and European markets. I am honored to have Steve join us, as I know his impact will be felt immediately.”
This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion and Q&Ahttps://agoracom.com/ir/LoopInsights/forums/discussion
About SG-retail: SG-retail works with a wide range of solution partners to create & deliver services to their vast range of clients. Our technology partnerships include market leading AI SaaS vendors in loyalty, CRM, analytics, customer experience, personalization and data monetization. For more information about SG-retail visit their website at: https://www.sg-retail.co.uk/
About Loop Insights: Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia.
This news release contains certain statements which constitute forward-looking statements or information.Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in thesecurities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:17 AM on Tuesday, October 13th, 2020
The global baby & adult nutrition company increases its strategic capital stake in ELSE to $9.75M via its subsidiary NewH2 Limited
NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.
With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares
Else intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations.
VANCOUVER, BC / October 13, 2020 /ELSE NUTRITION HOLDINGS INC.(TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition, is announcing today that NewH2 Limited, a subsidiary of Health and Happiness (H&H) International Holdings Limited, a Hong Kong Stock Exchange listed company (1112.HK) has increased their strategic investment in Else by C$4.0 million pursuant to a non-brokered private placement announced on September 15th.
The Company intends to use the proceeds of the offering to market its novel, plant-based baby and toddler nutrition products in North America alongside new product development operations. Furthermore, the investment provides the Company with the ability to accelerate and increase its production and supply capabilities, increase marketing activities and introduce its product(s) in new territories globally.
“We are very excited to continue to expand our relationship with H&H. They have been an immensely valuable partner and we look forward to working with their team in new market regions. We hear regularly from families across the globe who are seeking a non-dairy nutrition alternative for their children and we are fortunate to have a global partner supporting our endeavours for introduction of our products to store shelves in North America and beyond,” said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else.
Pursuant to the private placement the Company issued 2,224,111 (the “Units”) at a price of C$2.25 per Unit. Each Unit consisting of one common share and 0.50 share purchase warrants, with each whole warrant (a “Warrant”) entitling the holder to acquire one additional common share of the Company at an exercise price of C$3.25 per share for a period of thirty months from the closing date. With the completion this financing NewH2 owns 10,678,706 shares of the Company and 3,114,121 warrants, which will represent approximately 11.6% of the Company’s issued and outstanding common shares. The units issued will be subject to a 12 month hold period from date of closing.
The Company also pleased to announce that it has closed its previously announced upsized bought deal public offering, lead by Canaccord Genuity, of units (the “Units“) for aggregate gross proceeds of CAD$20.7 million, including the exercise of the over-allotment option in full (the “Offering“). The Company issued 9,200,000 Units at a price of CAD$2.25 per Unit, each Unit consisting of one common share of the Company (a “Share“) and one-half of one common share purchase warrant, with each whole warrant (a “Warrant“) entitling the holder to purchase one Share at the price of CAD$3.25 per Share until October 6, 2022. The Company has received approval from the TSX Venture Exchange (“TSXV“) to list the Warrants issued pursuant to the Offering, and the Warrants are posted for trading on the TSXV under the ticker symbol “BABY.WT” effective October 8, 2020.
Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com, and will soon be available on Amazon.com. Consumers can order single 22 oz cans and 4-packs.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
For more information, contact:
Ms. Hamutal Yitzhak, CEO, Co-Founder & Director ELSE Nutrition Holdings Inc. E: [email protected] P: +972(0)3-6445095
Mr. Sokhie Puar, Director of Else Nutrition Email: [email protected] Telephone: 604-603-7787
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 4:11 PM on Friday, October 9th, 2020
Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.
Herzliya, Israel and Calgary, Alberta–(October 9, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol (“CBD”) into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan’s licensed CBD loaded liposome platform technology (“LPT”) for injectable CBD.
The study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Berenholz, was conducted in The Hebrew University of Jerusalem laboratories on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT.
These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.
These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.
Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of The Hebrew University of Jerusalem in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which was the inventor of over 55 patent families, two of which underlie Doxil® – an FDA approved drug for breast cancer treatment. This unique technology platform may be implemented for several indications such as epilepsy, pain relief, and different inflammation and central nervous system disorders. A patent was filed on this technology on October 7, 2019.
Professor Chezy Berenholz stated, ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”
Iris Bincovich, Innocan’s CEO, added, “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”
About Innocan
Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 8:48 AM on Friday, October 9th, 2020
Announced that the Company’s ecommerce platform www.PlantX.com and www.PlantX.ca will begin featuring pet food products from Kirtana Inc.
The products PlantX will offer from Kirtana Inc. on its digital platform www.PlantX.com are all ethical and eco-friendly. The key ingredients used in the products include oats, maize, soy, pea protein, and sunflower seeds
“Launching the pet food section of PlantX.com with Kirtana Inc. products is very exciting,” said Sean Dollinger, PlantX founder. “Now we can offer a plant-based lifestyle to both human consumers and their pets.”
VANCOUVER, BC, Oct. 9, 2020 – PlantX Life Inc. (the “Company” or “PlantX“) (CSE: VEGA) (Frankfurt: WNT1) is pleased to announce that the Company’s ecommerce platform www.PlantX.com and www.PlantX.ca will begin featuring pet food products from Kirtana Inc.
PlantX adds plant-based pet food (CNW Group/PlantX Life Inc.)
The addition of plant-based pet foods allows PlantX, the digital face of the plant-based community and the one-stop-shop for everything plant-based, to further expand its category verticals. The Kirtana Inc. pet food offerings will be available to order in the new pet food section of the Company’s ecommerce platform PlantX.ca/vegan-pet-food.
PlantX is now able to offer a variety of pet food products from Kirtana Inc. including Evolution Diet, Ami and Benevo brands, featuring plant-based dry kibble formulas, an assortment of wet food in cans, and delicious vegan bone treats. Ami cat formula is well recognized among cat guardians, while Benevo offers a unique organic formula. Evolution Diet provides nutrition for dogs and cats of all life-stages with non-GMO and organic formulas.
The products PlantX will offer from Kirtana Inc. on its digital platform www.PlantX.com are all ethical and eco-friendly. The key ingredients used in the products include oats, maize, soy, pea protein, and sunflower seeds. The products have been formulated in accordance with AAFCO/FEDIAF nutritional standards to ensure that cats and dogs get 100% of the nutrients that they need to be healthy and thrive.
“Launching the pet food section of PlantX.com with Kirtana Inc. products is very exciting,” said Sean Dollinger, PlantX founder. “Now we can offer a plant-based lifestyle to both human consumers and their pets.”
“By adding pet food to the website, we have touched on a product that is meaningful around the world. We are very proud to be partnering with Kirtana Inc. It’s refreshing to know that the PlantX team goes through a lengthy process before partnering with brands. I am proud to invest in a company like PlantX that ensures all partners live up to these standards,” said Morris Hoffman, PlantX shareholder.
As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life.
Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes statements regarding the offering and availability of Kirtana Inc. products in the pet food section of the Company’s ecommerce platform, and the business and strategic plans of the Company.
By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Additional risk factors can also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 4:10 PM on Thursday, October 8th, 2020
Will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.
update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.
Herzliya, Israel and Calgary, Alberta–(October 8, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.
The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.
The YouTube livestream video will be available through livestream.innocanpharma.com
About Innocan
The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing Cannabidoil (“CBD”). Innocan Israel, a wholly owned subsidiary of the Company, and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 3:39 PM on Thursday, October 8th, 2020
Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:
Cannabis legalization is gaining momentum around the world.
Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).
So what is this going to translate into?
The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92%(Fortune Business Insights)
WHY WILL THIS TIME BE DIFFERENT?
Big promises, big IR budgets, big hype …. Big Letdown.
That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.
Investors will remember that the same thing happened during the dot-com era. As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.
But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses. What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.
The same thing is about to happen to the Cannabis sector
Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).
Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. These are the only known CBD cosmetics backed by clinical trials.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
For more information about the company, please check out the Avicanna HUB on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:
PatientVisits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows:
Increased CBD treatments from patients suffering increased anxiety;
Testing for individuals and families
Testing for local businesses and employees
Testing for enterprise level organizations across the country
At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006. We thought that would get your attention.
What Do They Do?
HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:
1. Retail Dispensaries
2. Wholesale
3. Cultivation and Processing
HIGHLIGHTS
Founded in 2006. One of the oldest and most respected cannabis retailers in California
Awarded one of the first six medical cannabis licenses in the USA
Operations have generated over $400M in cumulative sales since inception
Retail operations command 3% of California’s entire retail market
2020 Financials (Q1 + Q2)
○ Revenues $30,800,000
○ Gross Profit $14,000,000
○ EBITDA $1,100,000
Expected to generate approximately $62M – $65M in sales in 2020
Operate California’s only drive-through dispensary
Over 1,300 customers per day in Q2
Oakland dispensary is one of the largest retail cannabis locations in the world
2020E Guidance
~$44M Retail Revenue
~$21M Wholesale Revenue
~$62M – ~65M Total Revenue
For more information about the company, please check out the Harborside Inc hub on AGORACOM.
Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:
Revenues $USD
Q1 +317% YoY to $862,000
Q2 +3685% YoY to $8,500,000
TOTAL Q1 AND Q2
REVENUE $9.4M vs $428K = + 2096%
GROSS PROFIT $1.2M vs ($133K) = + 1002%
In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:
Hollister is also the creator of California’s most hash-infused pre-roll HashBone
For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
3 Fully Operating Divisions For Investor Diversification
Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
Superior Management Team
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
Together they have built one of the most formidable teams in the small cap cannabis world
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.
SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.
For more information about the company, please check out the Spyder Cannabis hub on AGORACOM.
Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle.
Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.
We’ll let these revenue numbers speak for themselves.
August 2020 CAD $3,809,000
July 2020 CAD $2,340,000
June 2020 CAD $2,712,000
The above represents an increase of 19%, over the same period in 2019.
QUARTERLY REVENUE $CAD
Q1 $7,600,000 Growth
Q2 $12,800,000 Growth
TOTAL Q1 AND Q2
REVENUE $20,400,000
GROSS PROFIT $2,154,357
The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.
The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.
For more information about the company, please check out the Thoughtful Brands hub on AGORACOM.
TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.
CAD$24.9M Revenue Run Rate from 10,000 sq.ft test facility
CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
Acquired two California companies,
High-end award winning edible producer Soldaze
Premium indoor cultivator and distributer Lyfted Farms
Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
2019 California Cannabis sales over $3B, industry currently fragmented
Direct to dispensary model, cutting out the middleman
REVENUES $CAD
Q1 $906,000
Q2 $4,300,000
TOTAL Q1 AND Q2
REVENUE $5,206,000
GROSS MARGIN $1,920,000
For more information about the company, please check out the TransCanna hub on AGORACOM.
Thanks for reading and discovering these great small cap cannabis companies. Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:
Avicanna is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. LEARN MORE.
